SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Frequently asked questions
What sector does SCYNEXIS, Inc (SCYX) operate in?
SCYNEXIS, Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is SCYNEXIS, Inc (SCYX) current stock price?
As of the latest data, SCYNEXIS, Inc stock price is $3.81, with a previous close of $3.79. SCYNEXIS, Inc gained $0.03 in the last trading session, representing a 0.66% increase.
What is SCYNEXIS, Inc (SCYX) current market capitalization?
SCYNEXIS, Inc market cap is approximately 37.91 million.
What is SCYNEXIS, Inc (SCYX) Earnings Per Share (EPS)?
The trailing EPS is -$0.91, and the forward EPS is -$2.32.
What is SCYNEXIS, Inc (SCYX) EBITDA?
SCYNEXIS, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 7.40 million.
Does SCYNEXIS, Inc (SCYX) pay dividends?
No. SCYNEXIS, Inc does not pay a dividend.
How did SCYNEXIS, Inc (SCYX) perform in its most recent earnings report?
In the last report (June 30, 2026), SCYNEXIS, Inc posted an EPS surprise of 20% and a revenue surprise of 192.54%.
When is SCYNEXIS, Inc (SCYX) next earnings report?
SCYNEXIS, Inc is expected to release its next earnings report on September 30, 2026.
What is SCYNEXIS, Inc (SCYX) beta (volatility) score?
SCYNEXIS, Inc has a beta of 1.109, meaning its volatility is roughly in line with the market.
